LakeShore Biopharma Co., Ltd Financials
This page shows LakeShore Biopharma Co., Ltd (LSBCF) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 3 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Financial Health Signals
Based on FY2025 annual data. Scores normalized against common benchmarks. How we calculate these scores
LakeShore Biopharma Co., Ltd has an operating margin of -14.0%, meaning the company retains $-14 of operating profit per $100 of revenue. This below-average margin results in a low score of 0/100, suggesting thin profitability after operating expenses. This is up from -77.8% the prior year.
LakeShore Biopharma Co., Ltd's revenue grew 6.0% year-over-year to $85.7M, a solid pace of expansion. This earns a growth score of 46/100.
LakeShore Biopharma Co., Ltd carries a low D/E ratio of 0.05, meaning only $0.05 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 100/100, indicating a strong balance sheet with room for future borrowing.
LakeShore Biopharma Co., Ltd's current ratio of 1.02 means current assets barely cover short-term liabilities. This tight liquidity results in a low score of 21/100, which could limit financial flexibility.
While LakeShore Biopharma Co., Ltd generated -$16.9M in operating cash flow, capex of $1.8M consumed most of it, leaving -$18.6M in free cash flow. This results in a low score of 0/100, reflecting heavy capital investment rather than weak cash generation.
LakeShore Biopharma Co., Ltd passes 5 of 9 financial strength tests. 1 of 4 profitability signals pass, 2 of 3 leverage/liquidity signals pass, both operating efficiency signals pass.
For every $1 of reported earnings, LakeShore Biopharma Co., Ltd generates $1.21 in operating cash flow (-$16.9M OCF vs -$13.9M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.
LakeShore Biopharma Co., Ltd earns $-5.5 in operating income for every $1 of interest expense (-$12.0M vs $2.2M). This narrow margin raises concern about the company's ability to service its debt if operating income declines.
Key Financial Metrics
LakeShore Biopharma Co., Ltd generated $85.7M in revenue in fiscal year 2025. This represents an increase of 6.0% from the prior year.
LakeShore Biopharma Co., Ltd's EBITDA was -$6.9M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 87.8% from the prior year.
LakeShore Biopharma Co., Ltd generated -$18.6M in free cash flow in fiscal year 2025, representing cash available after capex. This represents an increase of 61.1% from the prior year.
LakeShore Biopharma Co., Ltd reported -$13.9M in net income in fiscal year 2025. This represents an increase of 77.2% from the prior year.
LakeShore Biopharma Co., Ltd earned $-0.73 per diluted share (EPS) in fiscal year 2025. This represents a decrease of 28.1% from the prior year.
LakeShore Biopharma Co., Ltd held $15.0M in cash against $3.3M in long-term debt as of fiscal year 2025.
LakeShore Biopharma Co., Ltd had 21M shares outstanding in fiscal year 2025. This represents a decrease of 89.1% from the prior year.
LakeShore Biopharma Co., Ltd's gross margin was 82.5% in fiscal year 2025, indicating the percentage of revenue retained after direct costs. This is up 3.0 percentage points from the prior year.
LakeShore Biopharma Co., Ltd's operating margin was -14.0% in fiscal year 2025, reflecting core business profitability. This is up 63.7 percentage points from the prior year.
LakeShore Biopharma Co., Ltd's net profit margin was -16.3% in fiscal year 2025, showing the share of revenue converted to profit. This is up 59.3 percentage points from the prior year.
LakeShore Biopharma Co., Ltd invested $20.4M in research and development in fiscal year 2025. This represents a decrease of 52.2% from the prior year.
LakeShore Biopharma Co., Ltd invested $1.8M in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents a decrease of 71.6% from the prior year.
LSBCF Income Statement
| Metric | Q1'25 | Q1'24 | Q1'23 |
|---|---|---|---|
| Revenue | N/A | N/A | N/A |
| Cost of Revenue | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | N/A |
| R&D Expenses | N/A | N/A | N/A |
| SG&A Expenses | N/A | N/A | N/A |
| Operating Income | N/A | N/A | N/A |
| Interest Expense | N/A | N/A | N/A |
| Income Tax | N/A | N/A | N/A |
| Net Income | N/A | N/A | N/A |
| EPS (Diluted) | N/A | N/A | N/A |
LSBCF Balance Sheet
| Metric | Q1'25 | Q1'24 | Q1'23 |
|---|---|---|---|
| Total Assets | $190.5M-10.7% | $213.3M-14.8% | $250.3M |
| Current Assets | $117.3M-7.8% | $127.3M-15.6% | $150.8M |
| Cash & Equivalents | $15.0M-56.4% | $34.3M-36.3% | $53.9M |
| Inventory | $31.7M+10.6% | $28.7M+6.3% | $27.0M |
| Accounts Receivable | $69.8M+11.5% | $62.6M-7.1% | $67.4M |
| Goodwill | N/A | N/A | N/A |
| Total Liabilities | $120.9M-7.5% | $130.8M-9.3% | $144.3M |
| Current Liabilities | $114.9M+1.6% | $113.1M+17.9% | $95.9M |
| Long-Term Debt | $3.3M-76.5% | $14.0M-67.4% | $42.8M |
| Total Equity | $69.6M-15.6% | $82.5M-22.2% | $106.0M |
| Retained Earnings | -$335.4M-3.1% | -$325.2M-19.3% | -$272.7M |
LSBCF Cash Flow Statement
| Metric | Q1'25 | Q1'24 | Q1'23 |
|---|---|---|---|
| Operating Cash Flow | N/A | N/A | N/A |
| Capital Expenditures | N/A | N/A | N/A |
| Free Cash Flow | N/A | N/A | N/A |
| Investing Cash Flow | N/A | N/A | N/A |
| Financing Cash Flow | N/A | N/A | N/A |
| Dividends Paid | N/A | N/A | N/A |
| Share Buybacks | N/A | N/A | N/A |
LSBCF Financial Ratios
| Metric | Q1'25 | Q1'24 | Q1'23 |
|---|---|---|---|
| Gross Margin | N/A | N/A | N/A |
| Operating Margin | N/A | N/A | N/A |
| Net Margin | N/A | N/A | N/A |
| Return on Equity | N/A | N/A | N/A |
| Return on Assets | N/A | N/A | N/A |
| Current Ratio | 1.02-0.1 | 1.13-0.4 | 1.57 |
| Debt-to-Equity | 0.05-0.1 | 0.17-0.2 | 0.40 |
| FCF Margin | N/A | N/A | N/A |
Frequently Asked Questions
What is LakeShore Biopharma Co., Ltd's annual revenue?
LakeShore Biopharma Co., Ltd (LSBCF) reported $85.7M in total revenue for fiscal year 2025. This represents a 6.0% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is LakeShore Biopharma Co., Ltd's revenue growing?
LakeShore Biopharma Co., Ltd (LSBCF) revenue grew by 6% year-over-year, from $80.8M to $85.7M in fiscal year 2025.
Is LakeShore Biopharma Co., Ltd profitable?
No, LakeShore Biopharma Co., Ltd (LSBCF) reported a net income of -$13.9M in fiscal year 2025, with a net profit margin of -16.3%.
What is LakeShore Biopharma Co., Ltd's earnings per share (EPS)?
LakeShore Biopharma Co., Ltd (LSBCF) reported diluted earnings per share of $-0.73 for fiscal year 2025. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.
What is LakeShore Biopharma Co., Ltd's EBITDA?
LakeShore Biopharma Co., Ltd (LSBCF) had EBITDA of -$6.9M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
How much debt does LakeShore Biopharma Co., Ltd have?
As of fiscal year 2025, LakeShore Biopharma Co., Ltd (LSBCF) had $15.0M in cash and equivalents against $3.3M in long-term debt.
What is LakeShore Biopharma Co., Ltd's gross margin?
LakeShore Biopharma Co., Ltd (LSBCF) had a gross margin of 82.5% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.
What is LakeShore Biopharma Co., Ltd's operating margin?
LakeShore Biopharma Co., Ltd (LSBCF) had an operating margin of -14.0% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.
What is LakeShore Biopharma Co., Ltd's net profit margin?
LakeShore Biopharma Co., Ltd (LSBCF) had a net profit margin of -16.3% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.
What is LakeShore Biopharma Co., Ltd's free cash flow?
LakeShore Biopharma Co., Ltd (LSBCF) generated -$18.6M in free cash flow during fiscal year 2025. This represents a 61.1% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is LakeShore Biopharma Co., Ltd's operating cash flow?
LakeShore Biopharma Co., Ltd (LSBCF) generated -$16.9M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.
What are LakeShore Biopharma Co., Ltd's total assets?
LakeShore Biopharma Co., Ltd (LSBCF) had $190.5M in total assets as of fiscal year 2025, including both current and long-term assets.
What are LakeShore Biopharma Co., Ltd's capital expenditures?
LakeShore Biopharma Co., Ltd (LSBCF) invested $1.8M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does LakeShore Biopharma Co., Ltd spend on research and development?
LakeShore Biopharma Co., Ltd (LSBCF) invested $20.4M in research and development during fiscal year 2025.
How many shares does LakeShore Biopharma Co., Ltd have outstanding?
LakeShore Biopharma Co., Ltd (LSBCF) had 21M shares outstanding as of fiscal year 2025.
What is LakeShore Biopharma Co., Ltd's current ratio?
LakeShore Biopharma Co., Ltd (LSBCF) had a current ratio of 1.02 as of fiscal year 2025, which is considered adequate.
What is LakeShore Biopharma Co., Ltd's debt-to-equity ratio?
LakeShore Biopharma Co., Ltd (LSBCF) had a debt-to-equity ratio of 0.05 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is LakeShore Biopharma Co., Ltd's return on assets (ROA)?
LakeShore Biopharma Co., Ltd (LSBCF) had a return on assets of -7.3% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is LakeShore Biopharma Co., Ltd's cash runway?
Based on fiscal year 2025 data, LakeShore Biopharma Co., Ltd (LSBCF) had $15.0M in cash against an annual operating cash burn of $16.9M. This gives an estimated cash runway of approximately 11 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
What is LakeShore Biopharma Co., Ltd's Piotroski F-Score?
LakeShore Biopharma Co., Ltd (LSBCF) has a Piotroski F-Score of 5 out of 9, indicating neutral financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are LakeShore Biopharma Co., Ltd's earnings high quality?
LakeShore Biopharma Co., Ltd (LSBCF) has an earnings quality ratio of 1.21x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can LakeShore Biopharma Co., Ltd cover its interest payments?
LakeShore Biopharma Co., Ltd (LSBCF) has an interest coverage ratio of -5.5x, meaning it can struggle to cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.
How financially healthy is LakeShore Biopharma Co., Ltd?
LakeShore Biopharma Co., Ltd (LSBCF) scores 33 out of 100 on our Financial Profile, indicating weak overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.